For Australian Healthcare Professionals
As a professional, Eisai aims to support you in the treatment of your patients. In this section you will find information, including: Product Information Documents, and Consumer Medicines Informations (CMIs).
If you require further information, please contact Eisai Medical Information at Medinfo_Australia@eisai.net
Please follow the links to find further details of the medicines available in Australia.
Adverse events may also be reported to Eisai Australia Pty Ltd.
email: Safety_Australia@eisai.net
tel: +61 (03) 9832 9100
Oncology
-
Lenvima®
lenvatinib Product Information CMI -
Halaven®
eribulin mesilate Product Information CMI -
Gliadel®
carmustine Product Information CMI
Neurology
-
Fycompa®
perampanel Product Information CMI -
Inovelon®
rufinamide Product Information CMI -
Dayvigo®
lemborexant Product Information CMI
Lenvima®, Halaven®, Gliadel®, Fycompa®, Inovelon®, Dayvigo® are all registered trademarks of the Eisai Group, whose affiliate company in Australia is Eisai Australia Ltd, Level 2, 437 St Kilda Road, Melbourne VIC, 3004.
